iiinova — where your digital self keeps evolving

Reposted by Mike Pishvaian

Tumor Board Tuesday @tumorboardtuesday.bsky.social · 22/10/2025

7/18 #TumorBoardTuesday 👩🏻‍🏫Mini Tweetorial 4🏫 💊Several FDA👍PIK3CA-inhibitors: Capivasertib or Alpelisib or Inalvosalib 🤔 When and how do you PIK one of the PIK3CA of the 3 available? ☝️Inavolisib+Fulvestrant+Palbo is approved for 1st line mER+ BC after recurrence on/after adjuvant ET therapy

131

Reposted by Mike Pishvaian

Tumor Board Tuesday @tumorboardtuesday.bsky.social · 22/10/2025

7/18 #TumorBoardTuesday 👩🏻‍🏫Mini Tweetorial 4🏫 💊Several FDA👍PIK3CA-inhibitors: Capivasertib or Alpelisib or Inalvosalib 🤔 When and how do you PIK one of the PIK3CA of the 3 available? ✌️Alpelisib & Capivasertib are approved in 2nd line mER+ BC combined with fulvestrant 🔎 NGS results, Baseline A1C

121

Reposted by Mike Pishvaian

Tumor Board Tuesday @tumorboardtuesday.bsky.social · 22/10/2025

7/18 #TumorBoardTuesday 👩🏻‍🏫Mini Tweetorial 4🏫 💊Several FDA approved PIK3CA-inhibitors: Capivasertib or Alpelisib or Inalvosalib 🤔 When and how do you PIK one of the PIK3CA of the 3 available? 📎 pubmed.ncbi.nlm.nih.gov/33246021/

pubmed.ncbi.nlm.nih.gov

Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1 - PubMed

NCT02437318.

121

Reposted by Mike Pishvaian

Tumor Board Tuesday @tumorboardtuesday.bsky.social · 22/10/2025

8/18 #TumorBoardTuesday Back to our case🔎 👩‍🦳 Patient received Capivasertib + Fulvestrant due to PIK3CA mutation. 👉 Not yet considered endocrine resistant so would not move onto capecitabine, sacituzumab 👉 Tumor is HER2 negative so no role for trastuzumab deruxtecan

111

Reposted by Mike Pishvaian

Tumor Board Tuesday @tumorboardtuesday.bsky.social · 22/10/2025

8/18 #TumorBoardTuesday Back to our case🔎 👉 Everolimus + fulvestrant is not favored given the more targeted approach with Capivasterib for the PIK3CA mutation ✅ Tolerated therapy well with mild rash at start of treatment that resolved with antihistamines

111

Reposted by Mike Pishvaian

Tumor Board Tuesday @tumorboardtuesday.bsky.social · 22/10/2025

9/18 #TumorBoardTuesday ⏭️ Case 2 #TumorBoardTuesday #OncTwitter Case 2 👩‍🦳 62 y.o. postmenopausal female 💉 mBC to the🫁, ER 70%, PR 85%, HER2⛔[IHC 1] 🩻 confirmed⬆️Dz on 1L ribo/letrozole at C7 🏃‍♀️ ECOG PS 1. No co-morbidities. ⛔ Normal vital signs, labs 🩸Liquid Biopsy shows ESR1 mutation, TMB-High

211

Reposted by Mike Pishvaian

Tumor Board Tuesday @tumorboardtuesday.bsky.social · 22/10/2025

10/18 #TumorBoardTuesday 👩🏻‍🏫Mini Tweetorial 5🏫 👉 Recurred on adjuvant endocrine tx 👉 Recurred <2y after adjuvant endocrine tx 👉 ⬆️Dz<6mos of starting 1L mBC tx 👉 ⬆️Dz after any duration of >=2nd line of ET-based therapy 👉 Known ESR1 mutation [now have 2 Rx for ESR1m → elacestrant or imlunestrant]

111

Reposted by Mike Pishvaian

Tumor Board Tuesday @tumorboardtuesday.bsky.social · 22/10/2025

11/18 #TumorBoardTuesday 👩🏻‍🏫Mini Tweetorial 6🏫 EMERALD 👩‍🦳 2L metastatic HR+/HER2- received 💊 Elacestrant, an oral selective ER Degrader (SERD) ✅ 1-2 prior ET including CDK4/6i and < 1 chemo 💊 Elacestrant 400mg daily vs 💉fulvestrant or 💊AI ⬆️⬆️ PFS for prior💊 CDK4/6i > 12 mon with ESR1 mutated tumors

111

Reposted by Mike Pishvaian

Tumor Board Tuesday @tumorboardtuesday.bsky.social · 22/10/2025

11/18 #TumorBoardTuesday 👩🏻‍🏫Mini Tweetorial 6🏫 ⬆️ Elacestrant benefited all subgroups including: 🦴only, 🫁 visceral mets, > 3 mets ⬆️ Elacestrant benefited all🧬subgroups: ✔️ESR1+PIK3CA, ✔️ESR1+TP53, ✔️ESR1+HER2-low 🤢 Most common AE: N/V

ascopubs.org

ASCO Publications

111

Reposted by Mike Pishvaian

Tumor Board Tuesday @tumorboardtuesday.bsky.social · 22/10/2025

3/18 #TumorBoardTuesday 👩🏻‍🏫Mini Tweetorial 2🏫 CAPItello-291 👩‍🦳 mER+/HER2- breast cancer with PD on AI +/- CDK4/6i 💉2L Fulvestrant +/- capivasertib [oral, 🚫AKT plus.. 🚫PTEN, 🚫PIK3CA] ...continued

111

Reposted by Mike Pishvaian

Tumor Board Tuesday @tumorboardtuesday.bsky.social · 22/10/2025

3/18 #TumorBoardTuesday 👩🏻‍🏫Mini Tweetorial 2🏫 CAPItello-291 ✅ Capivasertib + fulvestrant ⬆️mPFS in AKT Pathway alterations [7.3m vs 3.1m] ✅ Capi+Fulvestrant benefited all subgroups including: 🦴only, 🫁 visceral mets, prior💊 CDK4/6i, prior ☣️chemo 📎https://www.nejm.org/doi/full/10.1056/NEJMoa2214131

nejm.org

Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer | NEJM

AKT pathway activation is implicated in endocrine-therapy resistance. Data on the efficacy and safety of the AKT inhibitor capivasertib, as an addition to fulvestrant therapy, in patients with horm...

211

Reposted by Mike Pishvaian

Tumor Board Tuesday @tumorboardtuesday.bsky.social · 22/10/2025

4/18 #TumorBoardTuesday 👩🏻‍🏫Mini Tweetorial 3🏫 CAPItello-291: Capivasertib Side effects 💊 Capivasertib taken 4 days on, 3 days off per week 🩺 Need baseline A1C < 8% 🚽 Most common AE: Diarrhea onset ~ day 8 [All grades 72%, G3/4 9.3%] ...continued

111

Reposted by Mike Pishvaian

Tumor Board Tuesday @tumorboardtuesday.bsky.social · 22/10/2025

4/18 #TumorBoardTuesday 👩🏻‍🏫Mini Tweetorial 3🏫 CAPItello-291: Capivasertib Side effects ☝️ Rash (12%) onset ~ day 12→ Pretreat with oral antihistamine, topical steroids 💉 Hyperglycemia (18%) onset ~ day 15; ⬇️ G3/G4 than other PIK3CA 📎https://www.esmoopen.com/article/S2059-7029(24)01466-2/fulltext

esmoopen.com

Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-2...

Capivasertib is a potent, selective pan-AKT inhibitor. In CAPItello-291, the addition of capivasertib to fulvestrant resulted in a statistically significant (P < 0.001) improvement in progression-free...

111

Reposted by Mike Pishvaian

Tumor Board Tuesday @tumorboardtuesday.bsky.social · 22/10/2025

5/18 #TumorBoardTuesday Back to our case🔎 💉 57yo ♀️ with mBC to the 🦴, liver, ER 100%, PR 95%, HER2⛔[IHC 0]-🩻confirmed⬆️Dz on 1L ribo/letrozole at C47 ✅ Normal labs (A1C=5.8) & VS 🩸Liquid Biopsy: +PIK3CA mutation, TP53 mutation, TMB-Low (4 mut/mb), High tumor fraction (> 5%) 👩🏻‍⚕️What 2L Tx is advised❓

111

Reposted by Mike Pishvaian

Tumor Board Tuesday @tumorboardtuesday.bsky.social · 22/10/2025

6/18 #TumorBoardTuesday POLL What 2L therapy would you give this patient❓ 1) Capecitabine 2) Trastuzumab deruxtecan 3) Sacituzumab govetican 4) Capivasertib + Fulvestrant 5) Everolimus + Fulvestrant

111

Reposted by Mike Pishvaian

Tumor Board Tuesday @tumorboardtuesday.bsky.social · 22/10/2025

2/18 #TumorBoardTuesday 👩🏻‍🏫Mini Tweetorial 1🏫 ...cont 📝Tissue-based assays or plasma-based assays (ctDNA) can be used ☝️Some alterations may be better detected by tissue-based assays like homozygous loss of PTEN or TMB-H. ☝️Liquid assays may reflect tumor heterogeneity more accurately

121

Reposted by Mike Pishvaian

Tumor Board Tuesday @tumorboardtuesday.bsky.social · 22/10/2025

2/18 #TumorBoardTuesday 👩🏻‍🏫Mini Tweetorial 1🏫 Actionable Mutations in 2L mER+/HER2- BC 🧬Several actionable mutations in 2L+ mBC: ESR1, PIK3CA, AKT, PTEN, BRCA (germline, somatic) 🔍Evaluation of acquired mutations at progression will help to direct therapy options Cont.....

111

Reposted by Mike Pishvaian

Tumor Board Tuesday @tumorboardtuesday.bsky.social · 22/10/2025

#TumorBoardTuesday POLL What would you do next❓ 1) Start capecitabine 2) Liquid biopsy to assess for actionable mutations 3) Start trastuzumab deruxtecan 4) Check tumor markers Ca 15-3 & Ca 27.29

111

Reposted by Mike Pishvaian

Tumor Board Tuesday @tumorboardtuesday.bsky.social · 22/10/2025

1/18 #TumorBoardTuesday @KennaKoehler & @drgattimays.bsky.social Case 1 👩‍🦳57 y.o. postmenopausal female 📋Well controlled DM (A1C = 5.8) 🏃‍♀️ECOG PS 0 💉Metastatic BC to bones, liver, ER 100%, PR 95%, HER2- [IHC 0] w/scan confirmed progression on 1L ribociclib/letrozole at C47 in bones ⛔ Normal labs & VS

111

Reposted by Mike Pishvaian

Tumor Board Tuesday @tumorboardtuesday.bsky.social · 21/10/2025

#TumorBoardTuesday 📢Join us Tuesday, 10-21-25 at 8PM ET as @drgattimays.bsky.social & @KennaKoehler 🗣️ Tx options after CDK4/6⛔️: What to consider in the 2nd line for HR+/HER2– mBC❓ RT and bring others into the discussion‼️

111

Reposted by Mike Pishvaian

Tumor Board Tuesday @tumorboardtuesday.bsky.social · 21/10/2025

#TumorBoardTuesday 🧠And while we finalize the case details, collect FREE #CME 👉🏽https://integrityce.com/tbt2025

111

Reposted by Mike Pishvaian

Tumor Board Tuesday @tumorboardtuesday.bsky.social · 21/10/2025

#TumorBoardTuesday ➡️Before @drgattimays.bsky.social & @KennaKoehler 🗣️ 2nd line Tx options for HR+/HER2– mBC, #BCSM tell us your connection to this medical🩺discussion 👇👇🏼👇🏾 1) Onc/Surg/Rad/IR/Gyn Onc 2) Other MD/APP/RN/Pharm D 3) Patient/Patient Advocate 4) Fellow/Resident/Trainee

111

Reposted by Mike Pishvaian

Tumor Board Tuesday @tumorboardtuesday.bsky.social · 21/10/2025

✅This #TumorBoardTuesday🗣️with @KennaKoehler & @drgattimays.bsky.social‬ is provided by @IntegrityCE 👍Supported by ed grants from Exelixis, Ferring, Ipsen, Lilly, Janssen Scientific Affairs, Merck & Taiho Oncology 🙏 👉🏽Info about 🆓 CME: integrityce.com/tbt2025

111

Reposted by Mike Pishvaian

Tumor Board Tuesday @tumorboardtuesday.bsky.social · 21/10/2025

#PreTest Q1️⃣#TumorBoardTuesday Free #CME integrityce.com/tbt2025 B4 @KennaKoehler & @drgattimays.bsky.social‬🗣️2nd-line Txs for #breastcancer, test your🧠with these 2❓

111

Reposted by Mike Pishvaian

Tumor Board Tuesday @tumorboardtuesday.bsky.social · 21/10/2025

🤔What 2L Tx would you offer a 45yo♀️w/ AKT mutated, ER+/HER2- mBC after⬆️Dz on ribociclib➕AI/OFS❓ 1) Capecitabine monotherapy 2) Capivasertib+fulvestrant 3) Elacestrant monotherapy 4) Everolimus + fulvestrant

111

Reposted by Mike Pishvaian

Tumor Board Tuesday @tumorboardtuesday.bsky.social · 21/10/2025

#PreTest Q2⃣#TumorBoardTuesday 🧐 A 75yo♀️w/ER+/HER2- PIK3CA+ mBC is starting 2L therapy with alpelisib+fulvestrant. Baseline A1C=6.1 & BMI is 33. What steps can limit risk for severe hyperglycemia❓ 1) Labs QW x 2, then monthly 2) Baseline A1C, then q3 mos 3) Consider metformin 4) All of the above

111

Mike Pishvaian @mpishvaian.bsky.social · 27/05/2025

#ASCO25 📢Join me & my colleagues EileenMOReilly, Gabi Chiorean, & Brian Wolpin to discuss #PancreaticCancer management in a case-based format 📅Friday, May 30th, 6:30- 8:00pm CDT 📍Sheraton Grand Chicago Riverwalk 4th Floor 📋Link to Registration: (tinyurl.com/mra3pt9s

tinyurl.com

Go To PER in Chicago

020

Mike Pishvaian @mpishvaian.bsky.social · 08/02/2025

@hopkinspress.bsky.social #GIOnc 📢Launching Day 2⃣‼️ 😀I am confident that today's sessions will be as GREAT as yesterday's sessions So - join us NOW for this 3rd Annual Johns Hopkins Updates in Gastrointestinal Cancers Conference

141

Mike Pishvaian @mpishvaian.bsky.social · 07/02/2025

@hopkinspress.bsky.social #GIOnc 📢We are underway‼️ 😀Join us today and tomorrow for our 3rd Annual Johns Hopkins Updates in Gastrointestinal Cancers Conference ✅As always - the conference is free to register and all sessions are available streaming🖥️on line integrityce.com/Hopkins25Str...

141

Reposted by Mike Pishvaian

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

Not sure about ampullary, but this ASCO 2024 poster found CLDN18.2 IHC 2+/3+ in 35% of small bowel adenocarcinomas (including 49% duodenal) doi.org/10.1200/JCO.2024.42.16_suppl.4176

121

Reposted by Mike Pishvaian

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

#PostTest Q1️⃣ #TumorBoardTuesday 👉🏽#CME Eval 🔗 integrityce.com/TBTeval24 👉🏽ALL CME🔗 integrityce.com/TBT2024 🤔What percentage of pancreatic adenocarcinoma cases typically express Claudin 18.2? 1) 30% 2) 50% 3) 70% 4) 90%

132

Reposted by Mike Pishvaian

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

#PostTest Q2️⃣ #TumorBoardTuesday 👉🏽 Free CME 🔗 integrityce.com/TBT2024 🧐 Which of the following would you select for a 78-year-old man w/ mPDAC (CLDN18.2, 45%; MSS; gBRCA WT) and disease progression after gemcitabine/abraxane❓ 1) FOLFIRINOX 2) Regorafenib trial 3) CLDN18.2 BiTe trial 4) Pembrolizumab

232

Reposted by Mike Pishvaian

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

27/31 #TumorBoardTuesday Back to our case🔎 Enrolled in CD3 x CLDN18.2 BiTE trial At 1 month, SD by CT but rising CA19-9 (206 -> 791)

143

Reposted by Mike Pishvaian

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

28/31 #TumorBoardTuesday 🏫Mini Tutorial 24🏫 How about CLDN18.2 BiTE+X combos? 1) BiTE+chemo Chemo increases immunogenicity, depletes immunosuppressive Tregs (CD3-targeting BiTEs recruit polyclonal T cells, including Tregs) NCT05365581: ASP2138 (CD3 x CLDN18.2) ± chemo

152

Reposted by Mike Pishvaian

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

29/31 #TumorBoardTuesday 🏫Mini Tutorial 25🏫 2) BiTE+ICI BiTEs -> inhibitory checkpoints upregulated KPC orthotopic model: CLDN18.2 x CD3 BiTE + αPD1 -> decreased tumor growth compared to BiTE or αPD1 alone doi.org/10.1053/j.gastro.2023.06.037

142

Reposted by Mike Pishvaian

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

30/31 #TumorBoardTuesday 🏫Mini Tutorial 26🏫 3) BiTE+OV Oncolytic virus -> tumor lysis -> T cell response SQ model of KPC w/ human CLDN18.2 in CD3ε humanized mice: OV-BiTE improved tumor control and survival compared to OV-GFP or PBS ctrl doi.org/10.1016/j.omto.2023.08.011

142

Reposted by Mike Pishvaian

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

31/31 #TumorBoardTuesday 🏫Mini Tutorial 27🏫 Choice of CLDN18.2 BiTE vs CAR-T? BiTE: off the shelf, continuous therapy CAR-T: autologous (takes time), one infusion doi.org/10.1186/s13045-021-01067-5

132

Reposted by Mike Pishvaian

Nick DeVito @ndevitomd.bsky.social · 05/02/2025

This is a good question, and we cannot reliably infer this from available transcriptional datasets as RNA doesn’t correlate to protein expression Time for a microarray? Patients with these rare cancers need therapeutic options.

021

Reposted by Mike Pishvaian

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

26/31 #TumorBoardTuesday 🏫Mini Tutorial 23🏫 58% panc pts had ≥3 prior lines PC: ORR 16.7%, mDOR 3.4 mos, CBR 33.3% At dose level 3, 2/5 PR in panc pts CRS mostly grade 1-2, 2 cases grade 3 ICANS grade 1 in 2 pts

153

Reposted by Mike Pishvaian

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

25/31 #TumorBoardTuesday 🏫Mini Tutorial 22🏫 2) Phase 1b/2, CT041 in CLDN18.2+ adv gastric or panc (ELIMYN18.2, NCT04404595) 19 patients: 7 gastric/GEJ cancer, 12 pancreatic cancer doi.org/10.1200/JCO.2024.42.3_suppl.356

143

Reposted by Mike Pishvaian

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

24/31 #TumorBoardTuesday 🏫Mini Tutorial 21🏫 Pooled analysis of CT041 in met panc (NCT03874897, NCT04581473) 24 pts with advanced panc ORR 16.7%, DCR 70.8% mPFS 3.3 mos, mOS 10 mos mDOR 9.5 mos, DOR 50% at 12 mos AEs: CRS, GI doi.org/10.1200/JCO.23.02314

142

Reposted by Mike Pishvaian

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

23/31 #TumorBoardTuesday 🏫Mini Tutorial 20🏫 96.9% CRS, all grade 1-2 8% gastric mucosal injury, 1 pt w/ grade 3 No DLTs, treatment related deaths, ICANS

133

Reposted by Mike Pishvaian

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

22/31 #TumorBoardTuesday 🏫Mini Tutorial 19🏫 ORR 38.8%, DCR 91.8%, mDOR 6.4 mos Among 10 pts with PDAC: 2 PR, 7 SD, 1 PD doi.org/10.1038/s41591-024-03037-z

Waterfall plot for CT041 (CLDN18.2 CAR-T)

242

Reposted by Mike Pishvaian

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

21/31 #TumorBoardTuesday 🏫Mini Tutorial 18🏫 CLDN18.2 CAR-T Trials: 1) Phase 1, CT041 (CLDN18.2 CAR-T) in CLDN18.2+ adv GI cancers (NCT03874897) AKA satricabtagene autoleucel (satri-cel) 98 pts got CT041: 75% gastric/GEJ, 10% panc, 8% intestinal, 4% BTC

131

Reposted by Mike Pishvaian

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

20/31 #TumorBoardTuesday 🏫Mini Tutorial 17🏫 5) Phase 1/2, PT886 (CD47 x CLDN18.2 bispecific) in adv gastric/GEJ or PC (TWINPEAK, NCT05482893) Promotes ADCC by NK cells, phagocytosis by macrophages Part C, cohort 2: 1L adv PDAC w/ CLDN18.2 ≥2+ ≥10%, PT886 + chemo Results pending

131

Reposted by Mike Pishvaian

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

19/31 #TumorBoardTuesday Mini Tutorial 16 4) Phase 1/2, PM1032 (CLDN18.2 x 41BB bispecific) in adv solid tumors (NCT05839106) Activates T and NK cells 30 patients, no DLTs, 66.7% CLDN18.2+ 14 gastric/GEJ, 10 panc, 5 other GI 17 CLDN18.2+ pts at ≥5 mg/kg: 2 PR, 7 SD

PM1032 (bispecific targeting CLDN18.2 and 41BB) in advanced solid tumors

142

Reposted by Mike Pishvaian

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

18/31 #TumorBoardTuesday 🏫Mini Tutorial 15🏫 Efficacy for 600 µg/kg in CLDN18.2 IHC 2+/3+ ≥10%: 27 pts, 8 PRs, 11 SDs, ORR 39.6%, DCR 70.4% DOR and PFS not reached

242

Reposted by Mike Pishvaian

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

15/31 #TumorBoardTuesday 🏫Mini Tutorial 12🏫 CLDN18.2 bispecific trials: 1) Phase 1, Q-1802 (PD-L1 x CLDN18.2) (NCT04856150) 17 pts w/ adv gastric, PC, or BTC, mostly ≥3 prior lines 2/9 PRs, 4/9 SDs AEs: n/v, abd pain, GERD 24.1% G3 TRAEs doi.org/10.1200/JCO.2023.41.4_suppl.382

252